Table 1

Overview of recent definitions of “refractory,” “high-risk,” and “ultra-high risk” CLL

SourceDisease state definedDefinition
IWCLL (2008) “Refractory” CLL Failure to achieve CR/PR, relapse within 6 mo of last treatment 
EBMT guideline (2007)27  “High-risk” (consider alloSCT) Nonresponse or early relapse (within 12 mo) after purine analogs 
  Relapse within 24 mo after having achieved a response with purine analog-based combination therapy or autologous transplantation 
  Patients with p53 abnormalities requiring treatment 
Stilgenbauer and Zenz (2010)17  “Ultra-high risk” Purine analog (or similar; ie, bendamustine)–refractory CLL 
  Early relapse (within 24 mo) after FCR (or FCR-like) with treatment indication 
  TP53 deletion/mutation and indication for treatment 
SourceDisease state definedDefinition
IWCLL (2008) “Refractory” CLL Failure to achieve CR/PR, relapse within 6 mo of last treatment 
EBMT guideline (2007)27  “High-risk” (consider alloSCT) Nonresponse or early relapse (within 12 mo) after purine analogs 
  Relapse within 24 mo after having achieved a response with purine analog-based combination therapy or autologous transplantation 
  Patients with p53 abnormalities requiring treatment 
Stilgenbauer and Zenz (2010)17  “Ultra-high risk” Purine analog (or similar; ie, bendamustine)–refractory CLL 
  Early relapse (within 24 mo) after FCR (or FCR-like) with treatment indication 
  TP53 deletion/mutation and indication for treatment 
Close Modal

or Create an Account

Close Modal
Close Modal